SPEGRA combines an integrase inhibitor with two nucleoside reverse transcriptase inhibitors, targeting HIV replication at multiple stages.
Recommended for:
Adults and adolescents diagnosed with HIV-1
Patients starting or switching therapy
Individuals seeking simplified once-daily dosing
Use under specialist HIV care
Treatment of HIV-1 infection in adults and adolescents weighing at least 35 kg
SPEGRA is taken orally once a day, with or without food. It is essential to maintain strict adherence to achieve consistent viral suppression and avoid resistance.
Contraindications:
Known hypersensitivity to any component
Severe hepatic impairment
Concurrent use with dofetilide
Side Effects:
Headache, insomnia
Nausea, diarrhoea
Elevated creatinine and liver enzymes
Skin rashes
Altered lipid levels